Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Solange Peters

Showing results (1-10 of 361) with videos related to

Pageof 37
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2015
Emerging Options After Progression During Crizotinib TherapySolange Peters
The New England Journal of Medicine|July 13, 2022
Setting the Benchmark for <i>KRAS</i> -Mutated NSCLCAntonio Passaro, Solange Peters
The New England Journal of Medicine|April 10, 2024
Adjuvant Alectinib in <i>ALK</i>-Rearranged NSCLC - Here and NowAntonio Passaro, Solange Peters
JAMA Oncology|July 26, 2019
Appraising the Tail of the Survival Curve in the Era of PD-1/PD-L1 Checkpoint BlockadeStefan Zimmermann, Solange Peters
Cancer Metastasis Reviews|May 16, 2015
Present standards and future perspectives in the treatment of metastatic non-small cell lung cancerStefan Zimmermann, Solange Peters
Cancer Cell|May 16, 2018
Genomic Features of Response to Combination Immunotherapy in Lung CancerMartin Früh, Solange Peters
Journal of the National Cancer Institute|July 18, 2009
Thalidomide in small cell lung cancer: wrong drug or wrong disease?Curzio Rüegg, Solange Peters
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2018
EML4-ALK Variant Affects ALK Resistance MutationsMartin Früh, Solange Peters
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2018
Delineating the Role of PD-1/PD-L1 Blockade in Advanced SCLCStefan Zimmermann, Solange Peters
The Lancet. Oncology|December 3, 2014
Pan-HER inhibition in EGFR wild-type non-small-cell lung cancerSolange Peters, Egbert Smit
Pageof 37

Showing results (1-10 of 361) with videos related to

Sort By:
Pageof 37
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2015
Emerging Options After Progression During Crizotinib TherapySolange Peters
The New England Journal of Medicine|July 13, 2022
Setting the Benchmark for <i>KRAS</i> -Mutated NSCLCAntonio Passaro, Solange Peters
The New England Journal of Medicine|April 10, 2024
Adjuvant Alectinib in <i>ALK</i>-Rearranged NSCLC - Here and NowAntonio Passaro, Solange Peters
JAMA Oncology|July 26, 2019
Appraising the Tail of the Survival Curve in the Era of PD-1/PD-L1 Checkpoint BlockadeStefan Zimmermann, Solange Peters
Cancer Metastasis Reviews|May 16, 2015
Present standards and future perspectives in the treatment of metastatic non-small cell lung cancerStefan Zimmermann, Solange Peters
Cancer Cell|May 16, 2018
Genomic Features of Response to Combination Immunotherapy in Lung CancerMartin Früh, Solange Peters
Journal of the National Cancer Institute|July 18, 2009
Thalidomide in small cell lung cancer: wrong drug or wrong disease?Curzio Rüegg, Solange Peters
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2018
EML4-ALK Variant Affects ALK Resistance MutationsMartin Früh, Solange Peters
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2018
Delineating the Role of PD-1/PD-L1 Blockade in Advanced SCLCStefan Zimmermann, Solange Peters
The Lancet. Oncology|December 3, 2014
Pan-HER inhibition in EGFR wild-type non-small-cell lung cancerSolange Peters, Egbert Smit
Pageof 37